TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Rating Lowered by ValuEngine

TG Therapeutics, Inc. (NASDAQ:TGTX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Monday, October 16th.

Other research analysts have also issued research reports about the company. Zacks Investment Research lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. BidaskClub upgraded TG Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 16th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and issued a $28.00 price target on shares of TG Therapeutics in a research report on Tuesday, October 3rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. TG Therapeutics currently has an average rating of “Buy” and an average price target of $25.11.

Shares of TG Therapeutics (NASDAQ TGTX) opened at 7.80 on Monday. TG Therapeutics has a 12 month low of $4.10 and a 12 month high of $15.35. The company’s market capitalization is $486.02 million. The company’s 50 day moving average price is $11.07 and its 200 day moving average price is $11.18.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.01. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 154.02% and a negative net margin of 68,806.59%. Analysts expect that TG Therapeutics will post ($1.84) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/valuengine-downgrades-tg-therapeutics-inc-tgtx-to-sell.html.

Several institutional investors have recently bought and sold shares of the company. FMR LLC raised its stake in shares of TG Therapeutics by 70.2% during the first quarter. FMR LLC now owns 6,451,713 shares of the biopharmaceutical company’s stock valued at $75,162,000 after acquiring an additional 2,660,949 shares in the last quarter. State Street Corp raised its stake in TG Therapeutics by 274.4% in the second quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock worth $26,515,000 after buying an additional 1,933,896 shares in the last quarter. Franklin Resources Inc. raised its stake in TG Therapeutics by 20.6% in the second quarter. Franklin Resources Inc. now owns 2,339,166 shares of the biopharmaceutical company’s stock worth $23,509,000 after buying an additional 398,916 shares in the last quarter. Vanguard Group Inc. raised its stake in TG Therapeutics by 14.3% in the second quarter. Vanguard Group Inc. now owns 2,046,427 shares of the biopharmaceutical company’s stock worth $20,566,000 after buying an additional 255,844 shares in the last quarter. Finally, Columbus Circle Investors raised its stake in TG Therapeutics by 39.0% in the second quarter. Columbus Circle Investors now owns 1,396,396 shares of the biopharmaceutical company’s stock worth $14,034,000 after buying an additional 391,975 shares in the last quarter. 49.86% of the stock is owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply